If you can't understand the follow-up professional description, you can read this text in two minutes
Overview of the condition
In mid-February 2020, Ms. Liu inadvertently touched the right waist mass, about the size of a steamed bun, and later imaging tests considered the possibility of malignancy. A puncture biopsy of the lesion is performed, and the pathology returns synovial sarcoma.
After the diagnosis of synovial sarcoma, two cycles of chemotherapy (doxorubicin + dacarbazine + ifosfamide) were given from 2020-3 to 2020-4 before surgery. The mass is significantly reduced after the first chemotherapy.
After undergoing neoadjuvant chemotherapy, Ms. Liu underwent lumbar tumor resection at Peking University People's Hospital in 2020-5, and the postoperative pathology: tumor cells were short fusiform, heterotypic, arranged in bundles, nuclear division was easy to see, foam tissue cell reactions were visible on the focal area, in line with unidirectional synovial sarcoma, showing post-chemotherapy manifestations.
Postoperatively, dacarbazine + ifosfamide + liposome paclitaxel 3 cycles of chemotherapy were performed.
section
general
small
know
know
Synovial sarcoma: Synovial sarcoma is a soft-tissue malignancy with a high degree of malignancy, which is more common in adolescents and middle-aged patients. The tumor originates in the joints, synovium, and tendon sheath synovial tissue. The site of the disease is mostly the large joints of the limbs, but it can also be seen in the forearms, thighs, and lower back. Clinical manifestations are mainly painless masses near the joints, and as the disease progresses, there may be different degrees of pain, vague pain, or dull pain, and even severe pain in the later stages, with significant pain at night. Treatment of synovial sarcoma is mainly based on surgical treatment, and neoadjuvant chemotherapy before surgery can achieve a better prognosis after surgery if it can produce results. Because it originates from tissues such as synovial tendon sheaths, it is easier to have lung metastases through the blood tract.
Unidirectional synovial sarcoma: synovial sarcoma can be roughly divided into three categories, unidirectional, bidirectional and dedifferentiated. Unidirectional type refers to its characteristics of only one kind of spindle cell, bi-directional type is mainly spindle cell and epithelial cell two characteristics, is currently the most common type of synovial sarcoma, dedifferentiation type refers to the unidirectional and bidirectional type on the basis of the visible components of small round cells.
Neoadjuvant chemotherapy: Neoadjuvant chemotherapy + surgery + postoperative chemotherapy "sandwich cookie" treatment can reduce the primary lesion before surgery and kill invisible metastatic cells early, which can increase the resection rate of surgery. Some patients are unable to undergo radical surgery or preserve some organs due to the scope of tumor invasion, and radical resection can be successfully performed after narrowing the scope of tumor invasion through neoadjuvant chemotherapy. Further chemotherapy after surgery can also reduce the probability of recurrent metastasis after surgery.
Ms. Liu is still very young, and the malignancy of synovial sarcoma is very high, and if no other intervention is carried out, the tumor is likely to continue to develop. Ms. Liu was very worried about this, ms. Liu and her family learned about Professor Zhang Minghui's NKT technology by Professor Zhang Minghui of Tsinghua University School of Medicine through the recommendation of friends, and consulted the demonstration cases of NKT cell therapy in detail, especially hoping to try to reduce the risk of metastatic recurrence in the future.
After reading Ms. Liu's medical records, Professor Zhang Minghui made the following analysis and judgment:
1. The age of onset of synovial sarcoma is overall small, the prognosis is poor, and the patient Ms. Liu is also very young.
2. The patient completes neoadjuvant chemotherapy + surgery + postoperative chemotherapy, and the traditional treatment plan is basically completed.
3. After both surgery and chemotherapy are completed, the next step is to prevent the occurrence of recurrent metastases. NKT treatment is the use of powerful immune cells to kill those tumor cells that may remain in the body that cannot be detected, and there are basically no side effects, which is very patient-friendly and can reduce the occurrence of metastatic recurrence.
Ms. Liu adopted NKT cell immunotherapy in August 2020, and has completed 14 courses of treatment for a total of 16 months (as of 2021.12), during which no obvious signs of tumor progression have been seen in multiple re-examinations, and the overall evaluation is stable!
Imagery
Imaging examination: 2021-8 review of systemic PET-CT showed no signs of recurrent metastasis; 2020-10 to 2022-2 review of lumbar vertebral MRI to show the right lumbar major muscle, no local mass manifestations were seen, lumbar 1-5 vertebral body and lumbar 3/4 plane spinal process internal fixator, consider postoperative changes.
quality of life
Ms. Liu's quality of life has been greatly improved. The mental state is very good, the energy to do things feels more energetic than in the past, and it returns to the state it was in before the illness. Normal life and work, not affected by the disease.
Conclusion
Ms. Liu achieved the expected results after using NKT cell therapy, and now after more than a year of treatment for a tumor with a high degree of malignancy, synovial sarcoma, the latest assessment results are still stable and have not seen progress.
Popular science knowledge, for reference only, individual patients are subject to clinical treatment.
NKT Classic Case Review
to view it